ClinicalTrials.gg
CompletedNCT00887549Updated Jun 19, 2012Results posted

A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer

A Phase 2 interventional study of pemetrexed and cisplatin in Non-Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-19.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
105th of 223
70 · median 64
Started
2009
with 20 others
Phase 2
128 of 227
12 open now
Registered
83rd of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 105th largest by enrollment of the 223 interventional ones that give a count, is one of 21 that started in 2009, is one of 128 in phase 2, and was the 83rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Thymidylate synthase (TS) is a substance the body produces naturally. The purpose of this research is to determine if there is a link between TS production and how well patients respond to treatment of non-squamous non-small cell lung cancer (NSCLC). The aim for the future is that doctors could have a better understanding in advance about which patients might respond well to pemetrexed based on how much TS they produce.

Read the detailed description

All patients on this study will receive 4 intravenous injections of the chemotherapy drugs pemetrexed and cisplatin (with each injection approximately 3 weeks apart). Patients who complete 4 such injections and respond well to their treatment may continue to receive an injection of chemotherapy drug pemetrexed (approximately every 3 weeks). In general terms, treatment will last until either the patient or the doctor decides that there is no clear benefit in continuing with the treatment.

TS levels will be measured from the tumour sample used to make the original diagnosis of NSCLC.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have Stage 3B or 4 Non-Small Cell Lung Cancer of the non- squamous type
  • Patients must at least be able to be physically mobile, take care of yourself and be able to perform light activities such as light housework or office work
  • Patients must not have had previous chemotherapy treatment for lung cancer
  • Patients must not have had radiotherapy in the last 30 days
  • Patients must have measureable tumor lesions according to the (RECIST) guidelines or disease that can be evaluated on computed tomography (CT) scan
  • Patients' test results assessing the function of their blood forming tissue, kidneys, liver and lungs are satisfactory
  • Women must be sterile, or on and men must be sterile or on contraception

Exclusion criteria

Exclusion Criteria:

  • Patients cannot have received other drugs within the last 30 days
  • Patients cannot have any serious, uncontrolled medical condition that might compromise their ability to take part in the study safely
  • Patients cannot have a current second primary malignant tumor
  • Patients cannot be having current treatment with any other anti-tumor therapy
  • Patients cannot have had a yellow fever vaccination within 30 days of enrolment
  • Patients who are unable to take vitamins (including injections of vitamin B12) or oral cortisone medication
  • Patients who are unable to stop taking more than 1.3 grams of aspirin on a daily basis or non-steroidal anti-inflammatory agents
  • Patients who are pregnant or breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Drug: pemetrexed · Drug: cisplatin

Interventions

  • Induction Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m\^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs

    Also known as: Alimta, LY231514

  • Induction Therapy: 75 mg/m\^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is time from first dose to first observation of disease progression/death (any cause). PFS is reported for participants with thymidylate synthase (TS) scores. For participants not known to have died by the data cut-off date and who do not have progressive disease, PFS will be censored at date of last objective progression-free disease assessment. For participants who receive systemic anticancer therapy after study drug discontinuation and prior to disease progression/death, PFS will be censored at date of last objective progression-free disease assessment prior to chemotherapy.

    Time frame: Baseline to measured progressive disease with follow-up every 6 weeks until progression of disease (up to 18 months after the last participant commenced induction therapy)

Secondary outcomes

  1. Percentage of Participants With Tumor Response (Tumor Response Rate)

    Tumor response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Percentage of participants with tumor response was determined by the number of participants with PR or CR (confirmed or not) divided by the total number of treated participants multiplied by 100.

    Time frame: Baseline to disease progression (up to 20 months)

  2. Percentage of Participants With Concordance Between Local and Central Histological Diagnosis

    A centralized pathology review on all enrolled participants was performed to confirm the histological diagnosis performed at the site. Upon review of the local diagnosis obtained at the respective site, the central reviewer established whether or not there was an agreement between the local and central diagnosis. The percentage of participants with concordance was defined as the number of participants for which there was an agreement divided by the number of treated participants (concordance rate) multiplied by 100.

    Time frame: Baseline

  3. Percentage of Participants Surviving at 18 Months (Overall Survival Rate)

    The percentage of participants surviving at 18 months was defined as the number of treated participants who had not died prior to 18 months from the date of their first dose divided by the total number of treated participants multiplied by 100. For participants who are alive, overall survival was censored at the last contact.

    Time frame: Baseline to date of death (up to 24.5 months)

07

Results

Posted Aug 30, 2011

Participant flow

Induction Therapy
Participant flow — Induction Therapy
MilestonePemetrexed
Started70
Completed43
Not completed27
Withdrew: Adverse event8
Withdrew: Physician decision1
Withdrew: Progressive disease13
Withdrew: Death due to study disease4
Withdrew: Death due to study drug toxicity1
Maintenance Therapy
Participant flow — Maintenance Therapy
MilestonePemetrexed
Started43
Completed0
Not completed43
Withdrew: Adverse event16
Withdrew: Physician decision1
Withdrew: Progressive disease25
Withdrew: Death due to adverse event1

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is time from first dose to first observation of disease progression/death (any cause). PFS is reported for participants with thymidylate synthase (TS) scores. For participants not known to have died by the data cut-off date and who do not have progressive disease, PFS will be censored at date of last objective progression-free disease assessment. For participants who receive systemic anticancer therapy after study drug discontinuation and prior to disease progression/death, PFS will be censored at date of last objective progression-free disease assessment prior to chemotherapy.

Time frame:
Baseline to measured progressive disease with follow-up every 6 weeks until progression of disease (up to 18 months after the last participant commenced induction therapy)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPemetrexed
Progression Free Survival (PFS)5.5 (3.9 to 6.9)
Statistical analysis
  • Pemetrexed · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 1.015 · 95% CI 1.008 to 1.021The Cox model, based upon participant level data, included PFS as dependent variable and TS score in the nucleus as independent variable.
SecondaryPercentage of Participants With Tumor Response (Tumor Response Rate)

Tumor response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST 1.0) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. Percentage of participants with tumor response was determined by the number of participants with PR or CR (confirmed or not) divided by the total number of treated participants multiplied by 100.

Time frame:
Baseline to disease progression (up to 20 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Tumor Response (Tumor Response Rate)
percentage of participantsPemetrexed
Percentage of Participants With Tumor Response (Tumor Response Rate)30 (19.62 to 42.13)
SecondaryPercentage of Participants With Concordance Between Local and Central Histological Diagnosis

A centralized pathology review on all enrolled participants was performed to confirm the histological diagnosis performed at the site. Upon review of the local diagnosis obtained at the respective site, the central reviewer established whether or not there was an agreement between the local and central diagnosis. The percentage of participants with concordance was defined as the number of participants for which there was an agreement divided by the number of treated participants (concordance rate) multiplied by 100.

Time frame:
Baseline
Reported as:
Number · percentage of participants
Percentage of Participants With Concordance Between Local and Central Histological Diagnosis
percentage of participantsPemetrexed
Percentage of Participants With Concordance Between Local and Central Histological Diagnosis78.6 (67.1 to 87.5)
SecondaryPercentage of Participants Surviving at 18 Months (Overall Survival Rate)

The percentage of participants surviving at 18 months was defined as the number of treated participants who had not died prior to 18 months from the date of their first dose divided by the total number of treated participants multiplied by 100. For participants who are alive, overall survival was censored at the last contact.

Time frame:
Baseline to date of death (up to 24.5 months)
Reported as:
Number · percentage of participants
Percentage of Participants Surviving at 18 Months (Overall Survival Rate)
percentage of participantsPemetrexed
Percentage of Participants Surviving at 18 Months (Overall Survival Rate)37.1 (25.89 to 49.52)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—41/70 (58.6%)67/70 (95.7%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventPemetrexed
NauseaGastrointestinal disorders7/70
VomitingGastrointestinal disorders7/70
Lower respiratory tract infectionInfections and infestations6/70
DiarrhoeaGastrointestinal disorders5/70
Non-cardiac chest painGeneral disorders5/70
FatigueGeneral disorders4/70
CellulitisInfections and infestations4/70
DyspnoeaRespiratory, thoracic and mediastinal disorders4/70
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/70
NeutropeniaBlood and lymphatic system disorders3/70
Most frequent other events
Showing 10 of 49
Most frequent other events
EventPemetrexed
FatigueGeneral disorders39/70
NauseaGastrointestinal disorders33/70
VomitingGastrointestinal disorders25/70
ConstipationGastrointestinal disorders23/70
Decreased appetiteMetabolism and nutrition disorders22/70
DiarrhoeaGastrointestinal disorders19/70
AnaemiaBlood and lymphatic system disorders15/70
Lacrimation increasedEye disorders15/70
RashSkin and subcutaneous tissue disorders15/70
Lower respiratory tract infectionInfections and infestations13/70

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed
Mean63.0 ± 9.42
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed
Female32
Male38
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed
Caucasian69
Asian1
Region of Enrollment
Region of Enrollment(participants)Pemetrexed
Ireland4
United Kingdom66
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed
0- Fully active24
1- Ambulatory, Restricted Strenuous Activity46
Pathological Diagnosis
Pathological Diagnosis(participants)Pemetrexed
Adenocarcinoma, not otherwise specified (NOS)34
Adenocarcinoma, acinar1
Adenocarcinoma, poorly differentiated20
Bronchioalveolar Carcinoma6
Carcinoma, Non-Small Cell, Lung (NSCL), (NOS)3
Carcinoma, NSC, Poorly Differentiated, Lung5
Carcinoma, undifferentiated1
Past and Current Tobacco Usage
Past and Current Tobacco Usage(participants)Pemetrexed
Never used tobacco products6
Ever used tobacco products64
08

Study locations

14 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dublin, Ireland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Derby, Derbyshire DE22 3NE, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Exeter, Devon EX2 5DW, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Maidstone, Kent ME16 9QQ, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Preston, Lancashire PR2 9HT, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liverpool, Merseyside L14 3PE, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Northwood, Middlesex HA6 2RN, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Scunthorpe, North Lincolnshire DN15 7BH, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Belfast, Northern Ireland BT9 7BL, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nottingham, Nottinghamshire NG5 1PD, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aberdeen, Scotland AB25 2ZN, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wolverhampton, West Midlands WV10 0QP, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grimsby, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manchester, M23 9LT, United Kingdom
09

References and documents

Publications

  • Fennell DA, Myrand SP, Nguyen TS, Ferry D, Kerr KM, Maxwell P, Moore SD, Visseren-Grul C, Das M, Nicolson MC. Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study. PLoS One. 2014 Sep 24;9(9):e107455. doi: 10.1371/journal.pone.0107455. eCollection 2014. PubMed 25250715 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jul 2010 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2009
First posted
Apr 24, 2009
Start
Apr 2009
Primary completionActual
Jul 2010
CompletionActual
Jun 2011
Results first posted
Aug 30, 2011
Last update
Jun 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00887549
Responsible party
Sponsor
First posted
Apr 24, 2009
Start date
Apr 2009
Primary completion
Jul 2010
Completion
Jun 2011
Results posted
Aug 30, 2011
Last update
Jun 19, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion